For example, dupilumab (DupixentTM), a humanized IgG4 Ab directed against human IL-4Rα, has been approved by U.S. Food & Drug Administration for the treatment of atopic dermatitis10,11 and is now under clinical trials for treating asthma, suggesting that IL-4/IL-13 dual blocking by IL-4Rα antagonist is a plausible way for treating allergic diseases12. The gene discussed is IL13; the disease is asthma.